Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results

#325

Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).

Aim(s): To characterize 5-HIAA response to treatment with everolimus and octreotide LAR in pts with advanced NET in the phase III RADIANT-2 trial.

Materials and methods: Pts with advanced NET received octreotide LAR (30mg IM q28 days) + everolimus 10mg daily (E+O) or placebo (P+O). 5-HIAA was measured at baseline and, if elevated (>ULN), measured on day one of each cycle. Incidence of 5-HIAA response (normalization or =50% reduction) was analyzed. Change from baseline over time was analyzed using the geometric mean.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Baudin E, Wolin E, Castellano D, Kaltsas G, Lebrec J,

Keywords: mTOR, everolimus, octreotide, 5-hydroxyindoleacetic acid, 5-HIAA,